IP Verse

New Combination - EP3034071

The patent EP3034071 was granted to Elanco Tiergesundheit on Dec 6, 2017. The application was originally filed on Dec 19, 2012 under application number EP15193269A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3034071

ELANCO TIERGESUNDHEIT
Application Number
EP15193269A
Filing Date
Dec 19, 2012
Status
Opposition Rejected
Mar 13, 2020
Grant Date
Dec 6, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOEHRINGER INGELHEIM VETMEDICASep 4, 2018BANSE & STEGLICH PATENTANWALTE PARTMBB -

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1490037
DESCRIPTIONWO2010055119
OPPOSITIONEP1490037
OPPOSITIONEP2793866
OPPOSITIONGB2394660
OPPOSITIONJP2005281283
OPPOSITIONUS2005203097
OPPOSITIONUS5364646
OPPOSITIONUS6162802
OPPOSITIONWO03075842
OPPOSITIONWO2006085208
OPPOSITIONWO2008095263
OPPOSITIONWO2010097501
OPPOSITIONWO2011111066
SEARCHUS2010035889
SEARCHUS2010183718
SEARCHWO2011111066

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "AMLODIPINE", Wikipedia, (20170517), URL: https://en.wikipedia.org/w/index.php?title=Amlodipine&oldid=780809103, XP055517988-
OPPOSITION- "Benazepril hydrochloride", the European Pharmacopoeia, (20110100), page 1454, XP055517980-
OPPOSITION- "chapter 1", SERNO et al., Granulieren, Aulendorf, DE, (20170000), pages 10 - 37, XP055518009-
OPPOSITION- "chapter 2 theory granulation", PARIKH, Handbook of Pharmaceutical Granulation technology, New York, (19970000), pages 7 - 23, XP055518002-
OPPOSITION- DESHPANDE et al., "BI-LAYER TABLETS- AN EMERGING TREND: A REVIEW", IJPSR, (20110000), vol. 2, no. 10, pages 2534 - 2544, XP055307645-
OPPOSITION- DIVYA et al., "Bilayer tablet technology: An overview", Journal of Applied Pharmaceutical Science, (20110000), vol. 01, no. 08, pages 43 - 47, XP055307644-
OPPOSITION- "Granulate", ROMPP CHEMIE LEXIKON, Stuttgart New York, (19900000), page 1641, XP055307733-
OPPOSITION- LACHMANN et al., The Theory and Practice of Industrial Pharmacy, (19860000), vol. 1086, pages 330 - 331, XP055517993-
OPPOSITION- LOMBARD, W., "Clinical efficacy of pimobendan (Vetmedin®) in double-blind clinical trial", Vetcontact Small Animal Practice, (20040000), URL: http://www.vetcontact.com/en/art.php?a=417>, XP055307639-
OPPOSITION- "Lotensin (benazepril hydrochloride) Tablet", Lotensin, (20070202), pages 1 - 18, URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4344b1_04_04_Lotensin%20Label.pdf>, XP055307648-
OPPOSITION- MADRON et al., "Survival and echocardiographic data in dogs with congestive heartfailure caused by mitral valve disease and treated by multiple drugs:A retrospective study of 21 cases", CVJ, (20110000), vol. 52, pages 1219 - 1225, XP055307638-
OPPOSITION- VETMEDIN, Freedom of Information Summary, (20070403), pages 141 - 144, URL: http://www.fda.gov/OHRMS/DOCKETS/98fr/2007-141-273-fois001.pdf>, XP055307713-
OPPOSITION- VOIGT,et al, "Die arzneiform als disperses system", VOIGT,et al, VOIGT,et al, Lehrbuch der pharmazeutischen Technologie, Gesundheit Berlin, (19730000), page 131, 132, 158, 159, 228,229, XP055517999-
OPPOSITION- GANA et al., "Kinetics of the acidic and enzymatic hydrolysis of benazepril HCI studied by LC", Journal of Pharmaceutical and Biomedical Analysis, (20020000), vol. 27, pages 107 - 116, XP055517984
OPPOSITION- O'GRADY et al., "Effect of Pimobendan on Case Fatality Rate in Doberman Pinscherswith Congestive Heart Failure Caused by Dilated Cardiomyopathy", J. Vet. Intern. Med., (20080000), vol. 22, pages 897 - 904, XP055307641
OPPOSITION- ATKINS et al., "Guidelines for the Diagnosis and Treatment of Canine Chronic Valvular Heart Disease", J. Vet. Intern. Med., (20090000), vol. 23, pages 1142 - 1150, XP055076510
SEARCH- HÄGGSTRÖM J ET AL, "Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study", JOURNAL OF VETERINARY INTERNAL MEDICINE, LIPPINCOTT, PHILADELPHIA, US, vol. 22, no. 5, ISSN 0891-6640, (20081001), pages 1124 - 1135, (20080711), XP009158237 [A] 1-10 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents